![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 43, 30764-30769, October 22, 1999
From the Presenilin proteins are involved in familial
Alzheimer's disease, a neurodegenerative disorder characterized by
massive death of neurons. We describe a direct interaction between
presenilin 1 (PS1) and Bcl-2, a key factor in the regulation of
apoptosis, by yeast two-hybrid interaction system, by
co-immunoprecipitation, and by cross-linking experiments. Our data show
that PS1 and Bcl-2 assemble into a macromolecular complex, and that
they are released from this complex in response to an apoptotic
stimulus induced by staurosporine. The results support the idea of
cross-talk between these two proteins during apoptosis.
Mutations of the presenilin
(PS)1 genes account up to
50% of all familial Alzheimer's disease cases (1-3). The homologous presenilin proteins are characterized by several transmembrane domains
and a large hydrophilic loop that faces the cytosol (4, 5). PS
holoproteins are rapidly processed in two stable NH2- and
COOH-terminal fragments that assemble into heterodimers (6). These are
localized within the endoplasmic reticulum, the Golgi apparatus, and
the nuclear envelope (7, 8). Potential functions of presenilins include
regulation of cDNA Cloning--
Alfa Bcl-2 cDNA was amplified by
reverse transcription-PCR from total RNA prepared from SY5Y cells
subjected to overnight treatment with 100 nM phorbol
12-myristate 13-acetate. PCR products were cloned in pCR3.1 expression
vector by TA cloning (Invitrogene).
Human full-length PS1 cDNA was amplified by reverse
transcription-PCR from total RNA prepared from HeLa cells, cloned in
pCR2.1 expression vector by TA cloning. Correct cDNA sequences were
confirmed by automated DNA sequencing.
Yeast Two-hybrid Screening--
pCR2.1-PS1 and
pCR2.1-PS1-hydrophilic-loop were digested by
EcoRI-SalI, and the resulting PS1 cDNA
fragments were subcloned into the Gal4 binding domain of pGBT9.
pCR3.1-Bcl-2 was digested by EcoRI-SalI, and the
resulting Bcl-2 cDNA fragment was subcloned into the Gal4
activation domain of pGAD424. The correct insertions and sequences of
both cDNAs were confirmed by automatic sequencing. Bait (pGBT9) and
prey (pGAD424) plasmids were introduced into CG 1945 yeast cells either
alone or together by using standard lithium acetate protocol. The
expression of fusion proteins was confirmed by Western blotting with
antibodies against PS1, the Gal4 binding domain, or Bcl-2. Transformed
yeasts were plated on histidine-deficient selective medium in the
presence of 25 mM 3-amino-1,2,3-triazol (3-AT). Synthesis
of Antibodies--
The monoclonal antibody 124 (mAb 124) directed
against residues 41-54 of Bcl-2 protein was purchased from Upstate
Biotechnology Inc. A polyclonal antiserum (Bcl-2
The polyclonal antiserum R4318 was raised against the keyhole limpet
hemocyanin-coupled peptide VQPFMDQLAFHQFYI-C, corresponding to
positions 453-467 of the carboxyl terminus of PS1. R4318 precipitated full-length PS1 from the nonionic detergent-soluble cellular fraction; the immunoreactive signal of the R4318 antibody was preadsorbed by the
corresponding uncoupled peptide (data not shown).
The polyclonal rabbit antiserum R9713 was raised against the keyhole
limpet hemocyanin-coupled peptide SQDTVAENDDGGFSEEWEAQ-C corresponding
to residues 324-343, and representing the NH2 terminus of
the putative caspase cleavage site. For immunoblotting, R9713 was
affinity-purified by adsorption to the corresponding antigenic peptide
immobilized to N-hydroxysuccinimide (NHS) HiTrap columns (Amersham Pharmacia Biotech). On immunoblots, R9713 detected the full-length PS1 and the PS1-CTF as 48- and 21-kDa bands, respectively, that were absorbed by preincubation with the peptide used for immunizations. Cellular amounts of this protein clearly increased upon
transfection of the cells with PS1 expression constructs.
Protein Extracts, Immunoprecipitation, and Western
Blotting--
Cells were washed twice with ice-cold phosphate-buffered
saline (PBS) and lysed with 2 mM potassium phosphate, pH
7.6, 0.1% Triton X-100 in the presence of a protease inhibitor
mixture. Lysates were centrifuged at 60,000 × g for 20 min, and protein concentrations in the supernatant fluids were
determined by BCA assay (Pierce). The lysates were precleared by
incubation with protein G-Sepharose (Amersham Pharmacia Biotech) for
2 h at room temperature. Immunoprecipitations were done at room
temperature by incubating overnight 200 µg of proteins with primary
antibodies, or with the preimmune R4318 serum previously bound to
protein G-Sepharose. Precipitated proteins were washed three times with lysis buffer, twice with PBS, and were eluted by boiling in
non-reducing SDS buffer. Proteins were separated by 4-20%
Tris-Tricine gel electrophoresis. Western blots were performed as
described previously (36) and probed with alkaline
phosphatase-conjugated anti-rabbit IgG ( Cross-linking of Protein Extracts--
Cells were lysed in 2 mM potassium phosphate (pH 7.6) in the presence of protease
inhibitors. NHS and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were freshly prepared in Me2SO and MES,
respectively, and were added to cell lysates at a final concentration
of 2 mM. The cross-linking reaction was done on ice and by
twice adding fresh linkers after 10 min. The reaction was stopped after
20 min with 9 mM glycine. Samples were solubilized with
0.1% Triton X-100 and centrifuged at 60,000 × g for
20 min.
Tissue Culture, Stable Transfections, Experimental Treatments,
and Reagents--
H9 human lymphoblastic cells were grown in RPMI 1640 medium (Life Technologies, Inc.) supplemented with 1 mM
L-glutamine, and with 10% fetal calf serum (Life
Technologies, Inc.), penicillin (100 units/ml), streptomycin (100 µg/ml) at 37 °C in a 5% CO2, 95% air humidified
chamber. H4 human neuroglioma cells were cultured in Dulbecco's
modified Eagle's medium with high glucose (Life Technologies, Inc.)
supplemented with 10% fetal calf serum (Life Technologies, Inc.),
penicillin (100 units/ml), streptomycin (100 µg/ml), at 37 °C in a
5% CO2/95% air humidified chamber. Twenty-four hours
after seeding, the semiconfluent layers of H4 cells were transfected
with 2 µg of pcDNA3 vector alone or with pCR3.1-Bcl-2 construct
and by using LipofectAMINE (Life Technologies, Inc.). At the same time,
cells were transfected with pCMV-
Subconfluent monolayers of stably transfected H4 cells were washed
twice with PBS, and exposed overnight to 100 nM
staurosporine in serum-free medium. Apoptosis was assayed by TUNEL
system according to manufacturer's instructions (Promega). 1 mM stock solution of staurosporine (Sigma) in
Me2SO was stored at Transient Transfections and Subcellular Fraction
Preparation--
Cos 7 cells were maintained in Dulbecco's modified
Eagle's medium with high glucose (Life Technologies, Inc.)
supplemented with 10% fetal calf serum (Life Technologies, Inc.),
penicillin (100 units/ml), streptomycin (100 µg/ml), at 37 °C in a
5% CO2, 95% air humidifying chamber. The day after
seeding, COS-7 cells were transiently transfected by LipofectAMINE with
the indicated plasmids; 24 h after transfection, cells were washed
twice with ice-cold PBS and harvested by using a cell lifter. Cells
were resuspended in buffer A (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1 mM EDTA, 200 mM
phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 20 µg/ml
leupeptin, 1 µg/ml pepstatin A, 5 mM dithiothreitol) and
homogenized in a glass-glass homogenizer using the loose pestle (25 strokes). The homogenate was incubated 10 min on ice and then centrifuged at 60,000 × g for 20 min at 4 °C to
generate the soluble cytosolic fraction (supernatant). The pellet was
resuspended in buffer B (Buffer A + 1% Nonidet P-40), homogenized
using a tight pestle (25 strokes), incubated on ice for 30 min, and
centrifuged at 60,000 × g for 20 min at 4 °C. The
supernatant was the particulate or membrane fraction. Loading of the
samples was normalized for the total content of cellular proteins
determined separately with Bradford or BCA method and double-checked
with Coomassie staining of the gels. Particulate and membrane fractions
were separated by 15% SDS-polyacrylamide gel electrophoresis. Western
blots were performed as described previously (36) and probed with
monoclonal antibody anti-cytochrome c and COII.
Interaction of PS1 with Bcl-2 in Yeast--
In order to test the
PS1/Bcl-2 interaction in vivo, we set up a yeast two-hybrid
interaction system. Full-length PS1, PS1 hydrophilic loop and
full-length Bcl-2 were expressed in yeast strain CG-1945 as fusion
proteins with a Gal4 DNA binding domain and a Gal4 transcription
activation domain, respectively. Whereas growth of yeasts expressing
either Bcl-2 or PS1 alone was either undetectable or limited, cells
harboring both fusion proteins were able to grow in the absence of
histidine (Fig. 1, lanes
1-3). In contrast to the interaction with full-length PS1, we did
not observe any interaction when the PS1 hydrophilic loop was expressed (data not shown). Positive control yeasts transformed with pVA3.1 and
pTD1 grew at higher rates (Fig. 1, lane 4). The
transactivation of the second reporter gene, lacZ, was
tested in a filter X-gal assay. Whereas the positive control colonies
started to turn blue after 2 h, none of the other transformed
yeasts expressed lacZ, even after overnight incubations with
X-gal.
Co-immunoprecipitation of PS1 with Bcl-2 Protein in Human Cell
Lines--
In order to determine whether Bcl-2 and PS1 interact in
human cell lines, we used co-immunoprecipitation assays of proteins extracted from H9 lymphoblastic and H4 neuroglioma cell lines. Proteins
immunoprecipitated by mAb 124 were analyzed by Western blot with the
PS1 polyclonal antiserum R4318, which recognized ~50-kDa full-length
PS1 both in H9 and in H4 cell lysates. Full-length PS1 was
co-immunoprecipitated with Bcl-2 in both cell lines (Fig. 2, A and B).
Cross-linking Reaction of PS1 and Bcl-2--
Cross-linking of cell
lysates of H4 cells reduced the electrophoretic mobility of the Bcl-2
immunoreactive signal in SDS gels (Fig.
3A), whereas cross-linked PS1
proteins migrated with a smear above 200 kDa (Fig. 3B).
Analysis of Bcl-2 immunoprecipitation after cross-linking presented the
same shift observed in protein extracts, with a Bcl-2 recovery by mAb
124 comparable in treated and untreated samples (Fig. 3A,
lanes 3 and 4). Cross-linkers did affect PS1
co-immunoprecipitation with Bcl-2, as evidenced by weaker signals at
~50 kDa, and by a concomitant signal at high molecular mass range of
the blots (Fig. 3B).
Identification of Stable Interactions of PS1 and Bcl-2 in
Bcl-2-transfected H4 Cells--
Reciprocal experiments carried out in
H9 and H4 cell lysates with different PS1 polyclonal antisera failed to
co-immunoprecipitate proteins recognized by mAb 124 (Fig.
4; data shown for H4 cell and R4318
polyclonal antiserum). To demonstrate immunoprecipitations of Bcl-2
with PS1, we stably overexpressed Bcl-2 in H4 cells; as compared with
native H4 cells, transfected cells had a higher level of Bcl-2 (Fig.
5A, lanes 1 and
2), whereas the amounts of PS1 co-immunoprecipitated by the
Bcl-2 antibody were similar in both untransfected and transfected cells
(Fig. 5A, lanes 4 and 6); different
PS1 polyclonal antisera R4318 and R9713 clearly co-immunoprecipitated
Bcl-2 only in transfected cells (Fig. 5B, lanes 3 and 4). In related control experiments, Bcl-2 immunoreactive signals were absent in R4318- and R9713-conjugated beads as well as in
proteins precipitated with the R4318 preimmune serum (Fig. 5B, lanes 1 and 2). To confirm that
the 26-kDa immunoreactive product detected by mAb 124 corresponded to Bcl-2, we preadsorbed the signal with the corresponding
peptide. Preadsorption eliminated the 26-kDa Bcl-2-related
signal, while ~29-kDa signal, caused by cross-reactivity to IgG
light chains (Fig. 5B, lane 7), remained unchanged.
Effects of Staurosporine-induced Apoptosis on PS1/Bcl-2 Interaction
and Mitochondrial Events Associated to PS1/Bcl-2--
Overnight
exposure to 100 nM staurosporine in serum-deficient media
induced apoptosis in roughly 40% of stably Bcl-2-transfected H4 cells,
as indicated by TUNEL assay (Fig. 6,
A and B). Western blots showed that
immunoreactive signals of Bcl-2 protein increased in lysates from cells
exposed to staurosporine (Fig.
7A, lanes 1 and
2) and that levels of full-length PS1 did not change
staurosporine (Fig. 7B, lanes 1 and
2). Despite increased Bcl-2 levels in protein extracts, its
recovery by immunoprecipitation following staurosporine exposure was
slightly lower as compared with control samples (Fig. 7A,
lanes 3 and 4); and apoptosis strongly reduced
co-immunoprecipitated full-length PS1 (Fig. 5B, lanes
3 and 4).
In order to determine at which step of the apoptotic cascade PS1 and
Bcl-2 interact each other, we transfected COS-7 cells with PS1 and
Bcl-2 expression constructs and we assessed cytochrome c
release from mitochondria. Transient transfections of PS1 increased the
release of cytochrome c; this increase was significantly
attenuated by co-transfection with Bcl-2 (Fig.
8). To rule out the possibility that
cytosolic preparations were contaminated with, we determined the
mitochondrial marker of COII in the subcellular fractions; COII was
present only in the membrane fraction (data not shown).
In this study we present evidence from yeast-two hybrid system,
from co-immunoprecipitations, and from cross-linking assays that PS1
interacts with Bcl-2. First, full-length PS1, but not the PS1
hydrophilic loop, used as bait, transactivated a histidine reporter
gene in the presence of a Bcl-2-Gal4 activation domain fusion protein.
The absence of lacZ induction in the same system could be
due either to weakness and instability of PS1 and Bcl-2 fusion complex
in yeast or to the requirement for a third interaction partner. The
yeast two-hybrid system was successfully used to identify interaction
between PS1 and We co-immunoprecipitated PS1 with a Bcl-2 antibody from human H9
lymphoblastic and H4 neuroglioma cells. Cross-linkers did neither
interfere sensibly with the Bcl-2 immunoreactive signals in proteins
extract nor with its recovery by mAb 124. In the presence of
cross-linkers, PS1 proteins were associated with a high molecular mass
complex over 200 kDa. This may be due to self-aggregation or to complex
formation with other putative partners. Co-immunoprecipitation of Bcl-2
and PS1 by mAb 124 was significantly affected by cross-linkers by
shifting the ~50-kDa full-length PS1 to a signal with a molecular mass higher than 200 kDa.
Reciprocal co-immunoprecipitation of Bcl-2 with a PS1 antibody was
demonstrated in H4 cells stably overexpressing Bcl-2.
Co-immunoprecipitation of PS1 with Bcl-2 was similar in transfected and
untransfected cells. Our data suggest that the interaction between the
two proteins occurs via the formation of a macromolecular complex,
rather than a 1:1 stoichiometric association. Apparently, increasing
amounts of Bcl-2 in transfected cells can facilitate its aggregation
into this macromolecular complex. This hypothesis is further supported by the known formation of both Bcl-2 homodimers and heterodimers with
other members of the Bcl-2 family (39, 40). Alternate interpretations
include the possibility that high cellular concentrations of Bcl-2 may
modify the intracellular milieu to the effect that interactions of
Bcl-2 with its partners are favored. The stably transfected H4 cells
used in this study were more resistant to apoptotic stimuli as compared
with the native, untransfected cells (data not shown). These data
confirm reports from other Bcl-2-overexpressing cell lines in which
apoptosis resistance was attributed to higher control of cellular
calcium homeostasis (41, 42). It is further known that PS proteins
interact with calcium-binding proteins (14, 15), and PS1 mutants
sensitize to apoptosis through a pathway that modulates intracellular
calcium ions homeostasis (32). If maintenance of intracellular calcium
concentration is a physiological function shared by PS1 and Bcl-2, we
can hypothesize that Bcl-2 overexpression may stabilize their
reciprocal association.
The broad inhibitor of protein kinases, staurosporine, induces
apoptosis in various cell lines by mediating a sustained increase of
intracellular calcium ion concentrations (43). In our experiments, staurosporine increased cellular levels of Bcl-2 protein that were not
followed by subsequent increase of immunoprecipitated Bcl-2 by mAb 124, suggesting the possibility that Bcl-2 may be sequestrated in complexes
not recognized by mAb 124 antibody. Full-length PS1 immunoreactivity
was unchanged by apoptosis, and instead apoptosis promoted the
dissociation of PS1 from Bcl-2, as demonstrated by reduced
co-immunoprecipitation of PS1 with mAb 124. Thus, reversible
association of Bcl-2 and PS1 could account for an anti-apoptotic role
played by the two proteins. Moreover, redistribution of cytochrome
c, one of the best known downstream activators of apoptotic
cascade, could be one of the crucial events influenced by PS1/Bcl-2
interaction; the interaction of PS proteins with Bcl-xL,
another anti-apoptotic member of Bcl-2 family and the subsequent change
in cytochrome c release, further support this
idea.2
A similar synergism exists in the interaction of Bcl-2 and SMN.
Mutations of SMN cause spinal muscular atrophy, a neurodegenerative disease characterized by neuronal apoptosis. Our data are consistent with similar interactions between PS1 and Bcl-2. In analogy to the role
of SMN in muscular atrophy, defective interaction of PS1 with Bcl-2 may
underlie the pathophysiology leading to AD. PS1 could thus have a role
in apoptosis by providing a part of Bcl-2 protein macromolecular
complex, and by liberating from the complex in response to an apoptotic
signal. Further characterization of the Bcl-2 interaction with familial
AD-associated PS1 mutants will address this possibility. The literature
on the role of presenilins in apoptosis is still controversial, in that
both sensitization to apoptosis and a protective effects were reported
(19-23, 44). Presenilins undergo alternative processing during
apoptosis, along with redistribution of their derivatives from an
intracellular membrane compartments to a Nonidet P-40-insoluble
cytoskeletal fraction (45). Apoptosis induced by death-effector domains
causes the formation of novel cytoplasmic structures, defined
death-effector filaments (DEF) that share solubility properties with
the cytoskeleton (46). Procaspases are among the major constituents of
DEF. Because presenilins are substrates of activated caspases it is
possible that dissociation of PS1 and Bcl-2 is associated with
subsequent recruitment in DEF. Insoluble intracellular filamentous
inclusions are hallmarks of many neurodegenerative conditions including
frontotemporal dementia, Parkinson's disease, dementia with Lewy
bodies, Huntington's disease (47), prion disease (48, 49), and AD
(50). Pathophysiologic mechanisms related to apoptosis could be common
scenarios in which such novel cytoplasmatic structures as DEF may alter
the native folding of different proteins such as A *
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.
§§
To whom correspondence should be addressed. Tel.: 39-30-3501709;
Fax: 39-30-3501366; E-mail: gbinetti@oh-fbf.it.
2
L. D'Adamio, personal communication.
The abbreviations used are:
PS, presenilin;
SMN, survival motor neuron protein;
AD, Alzheimer's disease;
PBS, phosphate-buffered saline;
NHS, N-hydroxysuccinimide;
MES, 2-(N-morpholino)ethanesulfonic acid;
DEF, death effector
filaments;
X-gal, 5-bromo-4-chloro-3-indolyl
Presenilin 1 Protein Directly Interacts with Bcl-2*
§,
§,
,
,
,
,
,
, and
§§
Istituto di Ricovero e Cura a Carattere
Scientifico (IRCCS) Centro S. Giovanni di Dio, Neurobiology Laboratory,
Alzheimer's Disease Unit, Via Pilastroni 4, 25123 Brescia, Italy, the
¶ Institute of Chemistry, Medical School, University of Brescia,
25124 Brescia, Italy, the
Department of Experimental Medicine
and Biochemical Sciences, University of Rome Tor Vergata, 00154 Rome,
Italy, the 
Department of Psychiatry
Research, University of Zurich, CH-8091 Zurich, Switzerland, and
the ** Department of Neurology, Harvard Medical School, Boston,
Massachusetts 02114-3139
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-amyloid precursor protein processing (9-11),
intracellular trafficking, regulation of transport (12, 13), regulation
of intracellular calcium homeostasis (14, 15), stabilization of the
cytoskeleton (16, 17), and participation in the Wg/Wnt signaling
pathway (18). Presenilins can also sensitize cells to apoptotic stimuli
leading to programmed cell death (19-23), raising the hypothesis that
PS interfere with specific steps of the apoptotic cascade. Apoptosis is
strongly inhibited by Bcl-2, the founding member of a large family of
proteins involved in the regulation of apoptosis (24, 25). Bcl-2 and its related proteins contribute to the formation of mitochondrial permeability transition pores (26), regulate the release of calcium
stores (27), and control the release of apoptogenic protease activators
from mitochondria to the cytosol (28, 29). Moreover, Bcl-2 family
members can modulate the apoptotic cascade by targeting regulatory
proteins to intracellular membranes (30). Bcl-2 is partially
co-localized with PS (31), and it protects cells against PS-related
apoptosis (32). Both proteins are involved in the maintenance of
intracellular calcium homeostasis; Bcl-2 regulates calcium fluxes from
the endoplasmic reticulum and mitochondria, and by targeting the
calcium-dependent protein phosphatase calcineurin (33). PS1
interacts with specific calcium-binding proteins, including calsenilin
and µ-calpain (14, 15). These observations suggest the possibility of
a direct cross-talk between Bcl-2 and PS. Proteins involved in the
regulation of neuronal apoptosis including the survival motor neuron
protein (SMN) are known to modulate Bcl-2 function by binding it (34,
35). To test the hypothesis that PS1 can bind Bcl-2, we performed yeast
two-hybrid interaction system, cross-linking experiments, and
co-immunoprecipitation assays in different cell lines, in the presence
or the absence of an apoptotic stimulus. Our results demonstrated
binding between the two proteins. These data provide new insights in
biological functions of presenilins and their possible role in the
pathogenesis of Alzheimer disease (AD).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase was subsequently tested by filter assay
(CLONTECH).
21) directed
against residues 1-205 of Bcl-2 protein was purchased from Santa Cruz
Biotechnology Inc. Monoclonal antibody anti-cytochrome c and
anti-cytochrome oxidase subunit II (COII) were purchased, respectively,
from PharMingen and Molecular Probes.
chain-specific) (Sigma) or
with goat anti-mouse IgG (H+L) (Kirkergaard & Perry Laboratories).
Gal, followed by a colorimetric
assay to test transfection efficiency. Clones were selected in 800 µg/ml G418 sulfate (Calbiochem). Resistant clones were picked by
using cloning cylinders, and were analyzed by Western blot with mAb 124 to confirm the overexpression of Bcl-2. Stable transfected H4 cells
expressing the Bcl-2 construct were maintained in G418 at a final
concentration of 800 µg/ml.
20 °C.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (33K):
[in a new window]
Fig. 1.
PS1 and Bcl-2 interaction analysis by yeast
two-hybrid screening. CG 1945 yeast cells were transformed with:
pGAD424-Bcl-2 Gal4 activation domain plasmid alone (lane 1),
pGBT9-PS1 Gal4 binding domain plasmid alone (lane 2), both
pGAD424-Bcl-2 and pGBT9-PS1 (lane 3), and control plasmid
pTD1.1 and pVA3.1 (lane 4). Yeasts were plated on selective
medium (
Trp,
Leu,
His) and 25 mM 3-AT for double
transformed cells, (
Trp,
His) 25 mM 3-AT for
PS1-overexpressing cells, and (
Leu,
His) 25 mM 3-AT for
Bcl-2-overexpressing cells. Colonies were then analyzed 3 days after
plating.

View larger version (14K):
[in a new window]
Fig. 2.
Co-immunoprecipitation of PS1 with Bcl-2 in
human cell lines. Western blot analysis was carried out with PS1
polyclonal antiserum R4318, after immunoprecipitation with Bcl-2 mAb
124 from H9 human lymphoblastic cells (A) and from native H4
human neuroglioma cells (B).

View larger version (29K):
[in a new window]
Fig. 3.
PS1 co-immunoprecipitation analysis after
cross-linking reaction. Lysates from stable trasfected H4 cells
were incubated twice for 10 min with NHS and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride linkers,
then immunoprecipitated with Bcl-2 mAb 124 after solubilization with
0.1% Triton X-100. Protein extracts (Prot. Extr.) treated
with or without cross-linkers (CL) (A,
lanes 1 and 2). The corresponding
immunoprecipitates (A, IPP, lanes 3 and 4) were analyzed by Western blot with Bcl-2 polyclonal
antibody
21. Protein extracts treated with or without cross-linkers
(B, lanes 1 and 2). The corresponding
co-immunoprecipitations (B, co-IPP, lanes 3 and
4) were analyzed by Western blot with R4318 anti-PS1
antiserum.

View larger version (46K):
[in a new window]
Fig. 4.
Absence of Bcl-2 co-immunoprecipitation by
PS1 polyclonal antibodies in native H4 cells. Protein extracts
(200 µg) from native H4 cells (lane 4) were
immunoprecipitated (IPP) with R4318 and analyzed by Western
blot with Bcl-2 mAb 124. In native cells (lane 3), in washed
R4318-conjugated beads (lane 1), and in proteins
immunoprecipitated with preimmune R4318 serum (lane 2), only
unspecific signal (~29 kDa) was detected.

View larger version (40K):
[in a new window]
Fig. 5.
PS1 and Bcl-2 interaction analysis by
immunoprecipitation assays. We stably transfected and
overexpressed Bcl-2 in H4 neuroglioma cells; protein extracts (10 µg)
from native H4 and stable transfected H4 cells were loaded onto 4-20%
Tris-Tricine gel electrophoresis, blotted, and analyzed with polyclonal
antiserum Bcl-2
21 (A, lanes 1 and
2). Cell lysates (200 µg) from native H4 cells and
Bcl-2-overexpressing (overexp.) H4 cells were
immunoprecipitated with mAb 124 and analyzed by Western blot with R4318
polyclonal antiserum; PS1 co-immunoprecipitation was similar in native
H4 and H4-transfected cells (A, lanes 4 and
6). Bcl-2 protein was co-immunoprecipitated
(co-IPP) by two different PS1 polyclonal antisera, R4318 and
R9713 by using protein extracts (Prot. Extr.) from
Bcl-2-overexpressing cells. Co-immunoprecipitated Bcl-2 were detected
as signals at 26 kDa (B, lanes 3 and
4); in washed R4318-conjugated beads (B,
lane 1) and in proteins immunoprecipitated (IP)
by preimmune R4318 serum (B, lane 2), only
unspecific signals, probably due to the IgG (~29 kDa), were detected.
Pre-adsorption of mAb 124 with its cognate peptide abolished 26-kDa
Bcl-2-related signals (B, lanes 8-10), while
unspecific bands remained unchanged (B, lane
7).

View larger version (49K):
[in a new window]
Fig. 6.
TUNEL assay in H4 cells incubated overnight
with 100 nM staurosporine. A, a,
cells grown under basal conditions; b, cells grown under
serum withdrawal; c, cells grown under serum withdrawal with
100 nM staurosporine. All pictures are taken at the same
magnification. Scale bar, 39 µm. B,
percentages of apoptotic cells are expressed as mean ± S.D.
(n = 3).

View larger version (16K):
[in a new window]
Fig. 7.
Apoptosis modified the interaction between
PS1 and Bcl-2. Stable transfected H4 cells were exposed overnight
to 100 nM staurosporine (STS) in medium without
serum (SW). Protein extracts (Prot. Extr., 10 µg) from cells grown in medium without serum or treated with
staurosporine were analyzed by Western blot with Bcl-2
21
(A, lanes 1 and 2) and with R4318
(B, lanes 1 and 2). Cell lysates (200 µg) were immunoprecipitated (IP) with Bcl-2 mAb 124 and
then tested by Western blot for immunoprecipitation with Bcl-2
polyclonal antiserum
21 (A, lanes 3 and
4) and co-immunoprecipitation with R4318 PS1 polyclonal
antiserum (B, lanes 3 and 4). Graphical
representation of blots is shown in C; staurosporine-treated
samples are expressed as percentage in respect to controls.

View larger version (42K):
[in a new window]
Fig. 8.
Transiently transfection of PS1 increased
cytochrome c release from mitochondria to
cytosol. We transfected COS-7 cells with pcDNA3, PS1 and Bcl-2
expression constructs (5 µg). Twenty-four hours after transfection,
cells were washed twice in ice-cold PBS and harvested by a cell lifter.
Proteins were extracted from cytosolic and membrane fractions. Equal
amounts of cytosol or membrane fractions (5 µg) were loaded onto 15%
SDS-polyacrylamide gel electrophoresis, blotted and analyzed with
monoclonal antibody anti-cytochrome c. Transient
transfections of PS1 increased the release of cytochrome c
(Cyt C) from membrane to cytosol fraction (A and
B, lane 1); this increase was sensibly rescued by
co-transfection with Bcl-2 (A and B, lane
3). Graphical representation of cytochrome c redistribution is
presented in C.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-amyloid precursor protein (37), filamin (16), and
-catenin (38). Together, these data suggest multiple interaction
partners of PS1, and possibly, promiscuity of their functional consequences.
, tau,
-synuclein, and prion protein to aggregated and insoluble forms.
Investigating whether presenilin 1 redistribution is followed by DEF
recruitment and deposition of PS1 containing filaments will provide
further insights to a common pathway by which distinct proteins are
involved in neurodegeneration.
![]()
FOOTNOTES
![]()
ABBREVIATIONS
-D-galactopyranoside;
mAb, monoclonal antibody;
COII, anti-cytochrome oxidase subunit II;
3-AT, 3-amino-1,2,3-triazol;
PCR, polymerase chain reaction;
Tricine, N-tris(hydroxymethyl)methylglycine;
TUNEL, terminal dUTP
nick-end labeling.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Sherrington, R.,
Rogaev, E. I.,
Liang, Y.,
Rogaeva, E. A.,
Levesque, G.,
Ikeda, M.,
Chi, H.,
Lin, C.,
Li, G.,
Holman, K.,
Tsuda, T.,
Mar, L.,
Foncin, J.-F.,
Bruni, A. C.,
Montesi, M. P.,
Sorbi, S.,
Rainero, I.,
Pinessi, L.,
Nee, L.,
Chumakov, I.,
Pollen, D.,
Brookes, A.,
Sanseau, P.,
Polinsky, R. J.,
Wasco, W.,
Da Silva, H. A. R.,
Haines, J. L.,
Periak-Vance, M. A.,
Tanzi, R. E.,
Roses, A. D.,
Fraser, P. E.,
Rommens, J. M.,
and St. George-Hyslop, P. H.
(1995)
Nature
375,
754-760[CrossRef][Medline]
[Order article via Infotrieve]
2.
Rogaev, E. I.,
Sherrington, R.,
Rogaeva, E. A.,
Levesque, G.,
Ikeda, M.,
Liang, Y.,
Chi, H.,
Lin, C.,
Holman, K.,
Tsuda, T.,
Mar, L.,
Sorbi, S.,
Nacmias, B.,
Piacentini, S.,
Amaducci, L.,
Chumakov, I.,
Cohen, D.,
Lannfelt, L.,
Fraser, P. E.,
Rommens, J. M.,
and St. George-Hyslop, P. H.
(1995)
Nature
376,
775-778[CrossRef][Medline]
[Order article via Infotrieve]
3.
Levy-Lahad, E.,
Wasco, W.,
Poorkaj, P.,
Romano, D. M.,
Oshima, J.,
Pettingell, W. H., Yu, C.,
Jondro, P. D.,
Schmidt, S. D.,
Wang, K.,
Crowley, A. C.,
Fu, Y.-H.,
Guenette, S. Y.,
Galas, D.,
Nemens, E.,
Wijsman, E. M.,
Bird, T. D.,
Shellenberg, G. D.,
and Tanzi, R. E.
(1995)
Science
269,
973-977 4.
Doan, A.,
Thinakaran, G.,
Borchelt, D. R.,
Slunt, H. H.,
Ratovitsky, T.,
Podlisny, M.,
Selkoe, D. J.,
Seeger, M.,
Gandy, S. E.,
Price, D. L.,
and Sisodia, S. S.
(1996)
Neuron
17,
1023-1030[CrossRef][Medline]
[Order article via Infotrieve]
5.
Lehmann, S.,
Chiesa, R.,
and Harris, D. A.
(1997)
J. Biol. Chem
272,
12047-12051 6.
Thinakaran, G.,
Borchelt, D. R.,
Lee, M. K.,
Slunt, H. H.,
Spitzer, L.,
Kim, G.,
Ratovisky, T.,
Davenport, F.,
Nordstedt, C.,
Seeger, M.,
Hardy, J.,
Levey, A. I.,
Gandy, S. E.,
Jenkins, N. A.,
Copeland, N. G.,
Price, D. L.,
and Sisodia, S. S.
(1996)
Neuron
17,
181-190[CrossRef][Medline]
[Order article via Infotrieve]
7.
Walter, J.,
Capell, A.,
Grunberg, J.,
Pesold, B.,
Schindzierlorz, A.,
Prior, R.,
Podlisny, M. B.,
Fraser, P.,
St. George-Hyslop, P. S.,
Selkoe, D. J.,
and Haass, C.
(1996)
Mol. Med.
2,
673-691[Medline]
[Order article via Infotrieve]
8.
De Strooper, B.,
Beullens, M.,
Contreras, B.,
Levesque, L.,
Craessaerts, K.,
Cordell, B.,
Moechars, D.,
Bollen, M.,
Fraser, P.,
St. George-Hyslop, P. S.,
and Van Leuven, F.
(1997)
J. Biol. Chem.
272,
3590-3598 9.
Tomita, T.,
Maruyama, K.,
Saido, T. C.,
Kume, H.,
Shinozaki, K.,
Tokuhiro, S.,
Capell, A.,
Walter, J.,
Grunberg, J.,
Haass, C.,
Iwatsubo, T.,
and Obata, T.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2025-2030 10.
Scheuner, D.,
Eckman, C.,
Jensen, M.,
Song, X.,
Citron, M.,
Suzuki, N.,
Bird, T. D.,
Hardy, J.,
Hutton, M.,
Kukull, W.,
Larson, E.,
Levy-Lahad, E.,
Viitanen, M.,
Peskind, E.,
Poorkaj, P.,
Schellenberg, G.,
Tanzi, R. E.,
Wasco, W.,
Lannfelt, L.,
Selkoe, D.,
and Younkin, S.
(1996)
Nat. Med.
2,
864-870[CrossRef][Medline]
[Order article via Infotrieve]
11.
De Strooper, B.,
Saftig, P.,
Craessaerts, K.,
Vanderstichele, H.,
Guhde, G.,
Annaert, W.,
Von Figura, K.,
and Van Leuven, F.
(1998)
Nature
391,
387-390[CrossRef][Medline]
[Order article via Infotrieve]
12.
Levitan, D.,
and Greenwald, I.
(1995)
Nature
377,
351-354[CrossRef][Medline]
[Order article via Infotrieve]
13.
Wong, P. C.,
Zheng, H.,
Chen, H.,
Becher, M. W.,
Sirinathsinghji, D. J.,
Trumbauer, M. E.,
Chen, H. Y.,
Price, D. L.,
Van der Ploeg, L. H.,
and Sisodia, S. S.
(1997)
Nature
387,
288-292[CrossRef][Medline]
[Order article via Infotrieve]
14.
Shinozaki, K.,
Maruyama, K.,
Kume, H.,
Tomita, T.,
Saido, T. C.,
Iwatsubo, T.,
and Obata, K.
(1998)
Int. J. Mol. Med.
1,
797-799[Medline]
[Order article via Infotrieve]
15.
Buxbaum, J. D.,
Choi, E. K.,
Luo, Y.,
Lilliehook, C.,
Crowley, A. C.,
Merriam, D. E.,
and Wasco, W.
(1998)
Nat. Med.
10,
1177-1181
16.
Zhang, W.,
Han, S. W.,
McKeel, D. W.,
Goate, A.,
and Wu, J. Y.
(1998)
J. Neurosci.
18,
914-922 17.
Takashima, A.,
Murayama, M.,
Murayama, O.,
Kohno, T.,
Honda, T.,
Yasutake, K.,
Nihonmatsu, N.,
Mercken, M.,
Yamaguchi, H.,
Sugihara, S.,
and Wolozin, B.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9637-9641 18.
Murayama, M.,
Tanaka, S.,
Palacino, J.,
Murayama, O.,
Honda, T.,
Sun, X.,
Yasutake, K.,
Nihonmatsu, N.,
Wolozin, B.,
and Takashima, A.
(1998)
FEBS Lett.
433,
73-77[CrossRef][Medline]
[Order article via Infotrieve]
19.
Deng, G.,
Pike, C. J.,
and Cotman, C. W.
(1996)
FEBS Lett.
397,
50-54[CrossRef][Medline]
[Order article via Infotrieve]
20.
Vito, P.,
Wolozin, B.,
Ganjei, J. K.,
Iwasaki, K.,
Lacanà, E.,
and D'Adamio, L.
(1996)
J. Biol. Chem.
271,
31025-31028 21.
Wolozin, B.,
Iwasaki, K.,
Vito, P.,
Ganjei, J. K.,
Lacanà, E.,
Sunderland, T.,
Zhao, B.,
Kusiak, J. W.,
Wasco, W.,
and D'Adamio, L.
(1996)
Science
274,
1710-1713 22.
Kim, T. W.,
Pettingell, W. H.,
Jung, Y. K.,
Kovacs, D. M.,
and Tanzi, R. E.
(1997)
Science
277,
373-376 23.
Zhang, Z.,
Hartmann, H.,
Do, V. M.,
Abramowski, D.,
Sturchler-Pierrat, C.,
Staufenbiel, M.,
Sommer, B.,
van de Wetering, M.,
Clevers, H.,
Saftig, P.,
De Strooper, B.,
He, X.,
and Yankner, B. A.
(1998)
Nature
395,
698-702[CrossRef][Medline]
[Order article via Infotrieve]
24.
Vaux, D. L.,
Cory, S.,
and Adams, J. M.
(1988)
Nature
335,
440-442[CrossRef][Medline]
[Order article via Infotrieve]
25.
Reed, J. C.
(1994)
J. Cell Biol.
124,
1-6 26.
Schendel, S. L.,
Xie, Z.,
Montal, M. O.,
Matsuyama, S.,
Montal, M.,
and Reed, J. C.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5113-5118 27.
Baffy, G.,
Miyashita, T.,
Williamson, J. R.,
and Reed, J. C.
(1993)
J. Biol. Chem.
268,
6511-6519 28.
Yang, J.,
Liu, X.,
Bhalla, K.,
Kim, C. N.,
Ibrado, A. M.,
Cai, J.,
Peng, T.-I.,
Jones, D. P.,
and Wang, X.
(1997)
Science
275,
1129-1132 29.
Kluck, R. M.,
Bossy-Wetzel, E.,
Green, D. R.,
and Newmeyer, D. D.
(1997)
Science
275,
1132-1136 30.
Hacker, G.,
and Vaux, D. L.
(1995)
Curr. Biol.
5,
622-624[CrossRef][Medline]
[Order article via Infotrieve]
31.
Krajewski, S.,
Tanaka, S.,
Takayama, S.,
Schibler, M. J.,
Fenton, W.,
and Reed, J. C.
(1993)
Cancer Res.
53,
4701-4714 32.
Keller, J. N.,
Guo, Q.,
Holtsberg, F. W.,
Bruce-Keller, A. J.,
and Mattson, M. P.
(1998)
J. Neurosci.
18,
4439-4450 33.
Shibasaki, F.,
Kondo, E.,
Akagi, T.,
and McKeon, F.
(1997)
Nature
386,
728-731[CrossRef][Medline]
[Order article via Infotrieve]
34.
Lefebvre, S.,
Burglen, L.,
Reboullet, S.,
Clermont, O.,
Burlet, P.,
Viollet, L.,
Benichou, B.,
Cruaud, C.,
Millasseau, P.,
and Zeviani, M.
(1995)
Cell
80,
155-165[CrossRef][Medline]
[Order article via Infotrieve]
35.
Iwahashi, H.,
Eguchi, Y.,
Yasuhara, N.,
Hanafusa, T.,
Matsuzawa, Y.,
and Tsujimoto, Y.
(1997)
Nature
390,
413-417[CrossRef][Medline]
[Order article via Infotrieve]
36.
Gasparini, L.,
Racchi, M.,
Benussi, L.,
Curti, D.,
Binetti, G.,
Bianchetti, A.,
Trabucchi, M.,
and Govoni, S.
(1997)
Neurosci. Lett.
231,
113-117[CrossRef][Medline]
[Order article via Infotrieve]
37.
Waragai, M.,
Imafuku, I.,
Takeuchi, S.,
Kanazawa, I.,
Oyama, F.,
Udagawa, Y.,
Kawabata, M.,
and Okazawa, H.
(1997)
Biochem. Biophys. Res. Commun.
239,
480-482[CrossRef][Medline]
[Order article via Infotrieve]
38.
Levesque, G., Yu, G.,
Nishimura, M.,
Zhang, D. M.,
Levesque, L., Yu, H.,
Xu, D.,
Liang, Y.,
Rogaeva, E.,
Ikeda, M.,
Duthie, M.,
Murgolo, N.,
Wang, L.,
VanderVere, P.,
Bayne, M. L.,
Strader, C. D.,
Rommens, J. M.,
Fraser, P. E.,
and St. George-Hyslop, P.
(1999)
J. Neurochem.
72,
999-1008[CrossRef][Medline]
[Order article via Infotrieve]
39.
Oltvai, Z. N.,
Milliman, C. L.,
and Korsmeyer, S. J.
(1993)
Cell
74,
609-619[CrossRef][Medline]
[Order article via Infotrieve]
40.
Hanada, M.,
Aime-Sempe, C.,
Sato, T.,
and Reed, J. C.
(1995)
J. Biol. Chem.
270,
11962-11969 41.
Distelhorst, C. W.,
Lam, M.,
and McCormick, T. S.
(1996)
Oncogene
12,
2051-2055[Medline]
[Order article via Infotrieve]
42.
Murphy, A. N.,
Bredesen, D. E.,
Cortopassi, G.,
Wang, E.,
and Fiskum, G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
9893-9898 43.
Kruman, I.,
Gou, Q.,
and Mattson, M. P.
(1998)
J. Neurosci. Res.
51,
293-308[CrossRef][Medline]
[Order article via Infotrieve]
44.
Roperch, J. P.,
Alvaro, V.,
Prieur, S.,
Tuynder, M.,
Nemani, M.,
Lethrosne, F.,
Piouffre, L.,
Gendron, MC.,
Israeli, D.,
Dausset, J.,
Oren, M.,
Amson, R.,
and Telerman, A.
(1998)
Nat. Med.
4,
835-838[CrossRef][Medline]
[Order article via Infotrieve]
45.
Gasparini, L.,
Moraschi, S.,
Ghidoni, R.,
Alberci, A.,
Benussi, L.,
Moratto, D.,
Trabucchi, M.,
Bianchetti, A.,
Growdon, J. H.,
Nitsch, R.,
and Binetti, G.
(1998)
Soc. Neurosci
24,
8
46.
Siegel, R. M.,
Martin, D. A.,
Zheng, L.,
Ng, S. Y.,
Bertin, J.,
Cohen, J.,
and Lenardo, M. J.
(1998)
J. Cell Biol.
141,
1243-1253 47.
Welch, W. J.,
and Gambetti, P.
(1998)
Nature
392,
23-24[CrossRef][Medline]
[Order article via Infotrieve]
48.
Schirmer, E. C.,
and Lindquist, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13932-13937 49.
DebBurman, S. K.,
Raymond, G. J.,
Caughey, B.,
and Lindquist, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
13938-13943 50.
Goedert, M.,
Spillantini, M. G.,
and Davies, S. W.
(1998)
Curr. Opin. Neurobiol.
8,
619-632[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. Maraver, C. E. Tadokoro, M. L. Badura, J. Shen, M. Serrano, and J. J. Lafaille Effect of presenilins in the apoptosis of thymocytes and homeostasis of CD8+ T cells Blood, November 1, 2007; 110(9): 3218 - 3225. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Lamarca, A. Sanz-Clemente, R. Perez-Pe, M. J. Martinez-Lorenzo, N. Halaihel, P. Muniesa, and J. A. Carrodeguas Two isoforms of PSAP/MTCH1 share two proapoptotic domains and multiple internal signals for import into the mitochondrial outer membrane Am J Physiol Cell Physiol, October 1, 2007; 293(4): C1347 - C1361. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Q. Wang, Y. Nakaya, Z. Du, T. Yamane, M. Shirane, T. Kudo, M. Takeda, K. Takebayashi, Y. Noda, K. I. Nakayama, et al. Interaction of presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2 Hum. Mol. Genet., July 1, 2005; 14(13): 1889 - 1902. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lamy, M. Ticchioni, A. K. Rouquette-Jazdanian, M. Samson, M. Deckert, A. H. Greenberg, and A. Bernard CD47 and the 19 kDa Interacting Protein-3 (BNIP3) in T Cell Apoptosis J. Biol. Chem., June 20, 2003; 278(26): 23915 - 23921. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, Y.-c. Shi, W. Gao, G. Mao, G. Zhao, S. Agrawal, G. M. Chisolm, D. Sui, and M.-Z. Cui The Novel Presenilin-1-associated Protein Is a Proapoptotic Mitochondrial Protein J. Biol. Chem., December 6, 2002; 277(50): 48913 - 48922. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Suh and F. Checler Amyloid Precursor Protein, Presenilins, and alpha -Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease Pharmacol. Rev., September 1, 2002; 54(3): 469 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tanahashi and T. Tabira Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein Hum. Mol. Genet., September 1, 2000; 9(15): 2281 - 2289. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-K. Choi, N. F. Zaidi, J. S. Miller, A. C. Crowley, D. E. Merriam, C. Lilliehook, J. D. Buxbaum, and W. Wasco Calsenilin Is a Substrate for Caspase-3 That Preferentially Interacts with the Familial Alzheimer's Disease-associated C-terminal Fragment of Presenilin 2 J. Biol. Chem., May 25, 2001; 276(22): 19197 - 19204. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||